Get the Stockscreener App
145.56
4.20%
5.87
After Hours:
145.44
-0.12
-0.08%
Axsome Therapeutics Inc stock is traded at $145.56, with a volume of 876.40K.
It is up +4.20% in the last 24 hours and up +13.77% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$139.69
Open:
$139.53
24h Volume:
876.40K
Relative Volume:
1.64
Market Cap:
$7.04B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-22.29
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
+5.63%
1M Performance:
+13.77%
6M Performance:
+35.37%
1Y Performance:
+56.23%
1-Day Range:
$138.90
$146.68
1-Week Range:
$136.00
$146.68
52-Week Range:
$75.56
$146.68
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
145.56 | 7.04B | 338.46M | -310.96M | -132.82M | -6.53 |
|
ARGX
Argen X Se Adr
|
929.61 | 55.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.02 | 110.91B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
197.40 | 41.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
376.63 | 40.48B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.31 | 72.89B | 14.25B | 4.58B | 3.88B | 41.77 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Axsome Therapeutics stock hits all-time high at 144.19 USD - Investing.com India
Axsome Therapeutics stock hits all-time high at 144.19 USD By Investing.com - Investing.com Australia
Will Axsome Therapeutics Inc. stock go up soonJuly 2025 Analyst Calls & AI Powered Buy and Sell Recommendations - newser.com
Envestnet Asset Management Inc. Grows Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Bank of New York Mellon Corp Has $21.26 Million Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
How Axsome Therapeutics Inc. stock compares to industry benchmarksProfit Target & Fast Gaining Stock Strategy Reports - newser.com
Historical volatility pattern of Axsome Therapeutics Inc. visualizedWeekly Trend Report & Smart Swing Trading Alerts - newser.com
How Axsome Therapeutics Inc. stock performs in rate cut cyclesPortfolio Risk Summary & Technical Pattern Based Buy Signals - newser.com
Axsome Therapeutics, Inc. $AXSM Shares Purchased by Los Angeles Capital Management LLC - MarketBeat
Candriam S.C.A. Trims Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Inc. stock momentum explainedEarnings Risk Report & Safe Entry Zone Identification - newser.com
(AXSM) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Tools to assess Axsome Therapeutics Inc.’s risk profileTrade Volume Summary & Daily Stock Trend Watchlist - newser.com
What Wall Street predicts for Axsome Therapeutics Inc. stock priceGap Up & Free Technical Confirmation Trade Alerts - newser.com
Can machine learning forecast Axsome Therapeutics Inc. recoveryJuly 2025 Institutional & Free Weekly Chart Analysis and Trade Guides - newser.com
How rising interest rates impact Axsome Therapeutics Inc. stock2025 Sector Review & Community Shared Stock Ideas - newser.com
Market reaction to Axsome Therapeutics Inc.’s recent newsInsider Selling & Low Risk High Win Rate Stock Picks - newser.com
Axsome Therapeutics Inc. recovery potential after sell offJuly 2025 Drop Watch & Community Shared Stock Ideas - newser.com
Why analysts recommend Axsome Therapeutics Inc. (19X) stock2025 Key Lessons & Daily Price Action Insights - Fundação Cultural do Pará
How Axsome Therapeutics Inc. (19X) stock reacts to Fed tighteningVolume Spike & Community Trade Idea Sharing - newser.com
Campbell & CO Investment Adviser LLC Purchases New Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Will Axsome Therapeutics Inc. stock sustain high P E ratios2025 Investor Takeaways & Daily Entry Point Trade Alerts - newser.com
How Axsome Therapeutics Inc. (19X) stock trades pre earningsM&A Rumor & Verified Swing Trading Watchlists - newser.com
Axsome Therapeutics (NASDAQ:AXSM) Hits New 12-Month HighWhat's Next? - MarketBeat
What candlestick patterns are forming on Axsome Therapeutics Inc.Gold Moves & Free AI Powered Buy and Sell Recommendations - newser.com
Avenue Therapeutics Sells Baergic Bio to Axsome - TipRanks
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
Claim your share of the $7.75M Axsome Therapeutics securities class action settlement - Claim Depot
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Axsome Therapeutics Inc. stock a buy on dipsJuly 2025 Fed Impact & Real-Time Market Trend Scan - newser.com
Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Axsome Therapeutics, Inc. Common StockAXSM - Markets Financial Content
Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics - MSN
2 Monster Stocks in the Making - Nasdaq
Connor Clark & Lunn Investment Management Ltd. Increases Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Can Axsome Therapeutics Inc. stock continue upward trendJuly 2025 Retail & Advanced Technical Signal Analysis - newser.com
Why hedge funds are buying Axsome Therapeutics Inc. stockJuly 2025 Intraday Action & Weekly Chart Analysis and Trade Guides - newser.com
Axsome Therapeutics Inc. stock trend forecastJuly 2025 Trade Ideas & Technical Entry and Exit Alerts - newser.com
Is Axsome Therapeutics Inc. forming a reversal pattern2025 Technical Overview & Real-Time Market Sentiment Alerts - newser.com
Axsome Therapeutics Eyes Baergic Bio: Is This the Next Big CNS Breakthrough? - Smartkarma
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.99%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):